A Randomized, Double‐Blind, Placebo‐Controlled Trial of a Novel Recombinant, Humanized, Anti‐Interleukin‐13 Monoclonal Antibody (RPC4046) in Patients with Active Eosinophilic Esophagitis: Results of the HEROES Study: 420. (October 2016)